Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Leucinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.37 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 7/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 4/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucinamide SCHEMBL1881755 | 1.00 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine Amide SCHEMBL1425294 | 1.00 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL241527 | 0.97 | — | — | |
| Leucinamide SCHEMBL1989213 | 0.97 | — | — | |
| Leucine Amide SCHEMBL241528 | 0.97 | — | — | |
| Leucine Amide SCHEMBL8081226 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL8081225 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine Amide SCHEMBL8052964 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucine Amide SCHEMBL9274582 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Leucinamide SCHEMBL8052962 | 0.95 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0397652-B1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORP (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | claimed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | claimed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| CN-118063385-A | Hapten for synthesizing cannabinoid ADB-BUTINACA, monoclonal antibody and application thereof | 中国药科大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | disclosed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | disclosed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0337714-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | disclosed |
| US-4452814-A | ANTITUMOR AGENTS | SUAMI T (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4384993-A | FRACTURING IN PRESENCE OF WATER SOLUBLE NITROGEN COMPOUND | JURIDICAL FOUNDATION THE CHEMO SERO-THERAPEUTIC RESEARCH INSTITUTE (JP) | 1983-05-24 | — | — | US | disclosed |
| EP-0035616-A1 | Production of immunoglobulin having a high monomer content | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute (JP) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | CACNA2D1 2337/4885CACNB3 4605/4885CACNA1C 4552/4885 |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | CACNA2D1 4710/4885CACNB3 4306/4885CACNA1C 4626/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | CACNA2D1 2735/4885CACNB3 4580/4885CACNA1C 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.